183 related articles for article (PubMed ID: 19770076)
1. Substrate competitive GSK-3 inhibitors - strategy and implications.
Eldar-Finkelman H; Licht-Murava A; Pietrokovski S; Eisenstein M
Biochim Biophys Acta; 2010 Mar; 1804(3):598-603. PubMed ID: 19770076
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).
Palomo V; Martinez A
Expert Opin Ther Pat; 2017 Jun; 27(6):657-666. PubMed ID: 27828716
[TBL] [Abstract][Full Text] [Related]
4. GSK-3 inhibition: achieving moderate efficacy with high selectivity.
Avrahami L; Licht-Murava A; Eisenstein M; Eldar-Finkelman H
Biochim Biophys Acta; 2013 Jul; 1834(7):1410-4. PubMed ID: 23369789
[TBL] [Abstract][Full Text] [Related]
5. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
Amar S; Belmaker RH; Agam G
Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
[TBL] [Abstract][Full Text] [Related]
6. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
8. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
[TBL] [Abstract][Full Text] [Related]
9. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Khan I; Tantray MA; Alam MS; Hamid H
Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.
Rippin I; Khazanov N; Shirley Ben Joseph ; Kudinov T; Berent E; Arciniegas Ruiz SM; Marciano D; Levy L; Gruzman A; Senderowitz H; Eldar-Finkelman H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218072
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.
Martinez A; Castro A; Dorronsoro I; Alonso M
Med Res Rev; 2002 Jul; 22(4):373-84. PubMed ID: 12111750
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
Medina M; Castro A
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):533-43. PubMed ID: 18600569
[TBL] [Abstract][Full Text] [Related]
13. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
15. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3--an overview of an over-achieving protein kinase.
Kockeritz L; Doble B; Patel S; Woodgett JR
Curr Drug Targets; 2006 Nov; 7(11):1377-88. PubMed ID: 17100578
[TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs.
Martinez A
Med Res Rev; 2008 Sep; 28(5):773-96. PubMed ID: 18271054
[TBL] [Abstract][Full Text] [Related]
18. Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor.
Eldar-Finkelman H; VanHook AM
Sci Signal; 2016 Nov; 9(454):c22. PubMed ID: 27902446
[TBL] [Abstract][Full Text] [Related]
19. Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor.
Licht-Murava A; Plotkin B; Eisenstein M; Eldar-Finkelman H
J Mol Biol; 2011 Apr; 408(2):366-78. PubMed ID: 21354422
[TBL] [Abstract][Full Text] [Related]
20. GSK-3: tricks of the trade for a multi-tasking kinase.
Doble BW; Woodgett JR
J Cell Sci; 2003 Apr; 116(Pt 7):1175-86. PubMed ID: 12615961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
